Astellas is shifting its investment focus toward more established modalities and later-stage opportunities, its chief ...
Following rumblings of a private equity bidding war late last year, Bain Capital has emer | Bain Capital is laying out 510 ...
Bain Capital, a global private investment firm, has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma ...
is acquiring Mitsubishi Tanabe Pharma Corporation in a multi-billion dollar deal that brings a portfolio of products marketed globally along with a drug pipeline spanning several key therapeutic ...
TOKYO, Feb 7 (Reuters) - U.S. private equity firm Bain Capital has bought Mitsubishi Tanabe Pharma in a deal worth 510 billion yen ($3.4 billion), saying it was encouraged by prospects of ...
Private equity firm Bain Capital agreed to acquire Mitsubishi Chemical Group’s pharmaceutical unit, adding to a dealmaking boom in Japan. The deal values Mitsubishi Tanabe Pharma at about ¥510 ...
both internal product development and external licensing and acquisitions, supported by Bain Capital investment Founded in 1678, Tanabe Pharma is headquartered in Doshomachi, Osaka, the birthplace ...
TOKYO & BOSTON--(BUSINESS WIRE)--Bain Capital, a leading global private investment firm, today announced it has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation ...
Independent company plans significant investment in innovation, both internal product development ... a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation (“Tanabe Pharma ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback